In May 2011, the Company received a short term unsecured loan facility of up to $1.7 million from SynBio (the “SynBio Loan”), an affiliate of the Company. In connection with the APA, the Company made a series of payments during the first two quarters of 2016 totaling approximately $0.3 million to creditors of Kevelt. Pursuant to the APA, such payments are considered direct offsets to the loan with SynBio.

In December 2016, the Company entered into an agreement with SynBio, Pharmsynthez, and Kevelt which settled all amounts owed on the SynBio Loan, Kevelt services provided to Xenetic in connection with the XBIO-101 Phase 2 project, and the purchase of drug candidate supply from Kevelt sufficient to meet the needs of the XBIO-101 Phase 2 clinical trial. Pursuant to this agreement, the Company transferred approximately $0.6 million to the counter parties. No amounts were outstanding under the SynBio Loan as of December 31, 2017 and 2016, respectively.

The Company has entered into various research, development, license and supply agreements with Shire, SynBio, Serum Institute and Pharmsynthez, each a related party whose relationship, ownership, and nature of transactions is disclosed within other sections of these footnotes.

During the years ended December 31, 2017 and 2016, the Company received research and consulting services from a director of Pharmsynthez, a controlling stockholder of the Company. The total amount of services received was approximately $0.1 million for the years ended December 31, 2017 and 2016, respectively. This consulting agreement was terminated in July 2017.

Please refer to Note 4, Significant Strategic Drug Development Collaborations – Related Parties, Note 8, Hybrid Debt Instruments, and Note 11, Stockholder’s Equity, for details on arrangements with collaboration partners and non-employee directors that are also related parties.